AI assistant
IMUGENE LIMITED — Major Shareholding Notification 2023
Oct 2, 2023
65124_rns_2023-10-02_2cf474e4-ae03-44c5-bf10-9d89fbb81f08.pdf
Major Shareholding Notification
Open in viewerOpens in your device viewer
ASX Announcement
==> picture [177 x 30] intentionally omitted <==
Distribution Schedule and Top 20
Sydney, Australia, 3 October 2023: Imugene Limited (ASX:IMU) (Imugene, or the Company) is pleased to provide the Distribution Schedule and Top 20 for the options quoted today in accordance with ASX Listing Rule 3.10.5.
Release approved by the Company Secretary on behalf of the Board.
For more information please contact:
Leslie Chong
Managing Director and Chief Executive Officer
Investor Enquiries
Media Enquiries
Matt Wright [email protected]
Follow us on Twitter @TeamImugene Like us on Facebook @Imugene Connect with us on LinkedIn @Imugene Limited View us on YouTube @Imugene Limited
IMUGENE LIMITED ACN 009 179 551
WWW.IMUGENE.COM
==> picture [42 x 41] intentionally omitted <==
About Imugene (ASX:IMU)
Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. Our pipeline also includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T’s for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.
Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene’s immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.
IMUGENE LIMITED ACN 009 179 551
WWW.IMUGENE.COM
ABN: 27 152 260 814
==> picture [9 x 9] intentionally omitted <==
1300 288 664 (within australia) +61 2 9698 5414 (international) [email protected] www.automic.com.au
==> picture [9 x 9] intentionally omitted <==
==> picture [9 x 9] intentionally omitted <==
==> picture [9 x 9] intentionally omitted <==
Holdings Range Report
Imugene Limited
Security Class(es): IMUOP38 - UNL OPT @ $0.118 EXP 31/08/2026
As at Date: 03-Oct-2023
| Holding Ranges | Holders | Total Units | % Issued Share Capital |
|---|---|---|---|
| above 0 up to and including 1,000 | 0 | 0 | 0.00% |
| above 1,000 up to and including 5,000 | 0 | 0 | 0.00% |
| above 5,000 up to and including 10,000 | 0 | 0 | 0.00% |
| above 10,000 up to and including 100,000 | 734 | 37,268,316 | 5.02% |
| above 100,000 | 683 | 704,667,432 | 94.98% |
| TOTALS | 1,417 | 741,935,748 | 100.00% |
==> picture [10 x 10] intentionally omitted <==
Report generated on 03-Oct-2023 at 11:20 AM
1300 288 664 (within australia) +61 2 9698 5414 (international) [email protected] www.automic.com.au
ABN: 27 152 260 814
==> picture [9 x 9] intentionally omitted <==
==> picture [9 x 9] intentionally omitted <==
==> picture [9 x 9] intentionally omitted <==
==> picture [9 x 9] intentionally omitted <==
Top Holders Grouped Report
Imugene Limited
Security Class(es): IMUOP38 - UNL OPT @ $0.118 EXP 31/08/2026 Display Top: 20
As at Date: 03-Oct-2023
| Position | Holder Name | Holding | % IC |
|---|---|---|---|
| 1 | CITICORP NOMINEES PTY LIMITED | 128,355,218 | 17.30% |
| 2 | MERRILL LYNCH (AUSTRALIA) NOMINEES PTY LIMITED | 121,428,571 | 16.37% |
| 3 | BILGOLA NOMINEES PTY LIMITED | 35,714,286 | 4.81% |
| 4 | BNP PARIBAS NOMINEES PTY LTD |
24,455,275 | 3.30% |
| 5 | HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED - A/C 2 | 24,166,666 | 3.26% |
| 6 | HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED-GSCO ECA | 23,809,524 | 3.21% |
| 7 | J P MORGAN NOMINEES AUSTRALIA PTY LIMITED | 23,224,452 | 3.13% |
| 8 | NATIONAL NOMINEES LIMITED | 19,185,787 | 2.59% |
| 9 | HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED | 13,818,443 | 1.86% |
| 10 | MORGAN STANLEY AUSTRALIA SECURITIES (NOMINEE) PTY LIMITED |
11,904,762 | 1.60% |
| 11 | UBS NOMINEES PTY LTD | 7,785,457 | 1.05% |
| 12 | DRM TECHNOLOGIES PTY LTD | 4,866,698 | 0.66% |
| 13 | BNP PARIBAS NOMINEES PTY LTD HUB24 CUSTODIAL SERV LTD |
4,294,636 | 0.58% |
ABN: 27 152 260 814
==> picture [9 x 9] intentionally omitted <==
1300 288 664 (within australia) +61 2 9698 5414 (international) [email protected] www.automic.com.au
==> picture [9 x 9] intentionally omitted <==
==> picture [9 x 9] intentionally omitted <==
==> picture [9 x 9] intentionally omitted <==
| Position | Holder Name | Holding | % IC | |
|---|---|---|---|---|
| 14 | ABN AMRO CLEARING SYDNEY NOMINEES PTY LTD |
3,940,785 | 0.53% | |
| 15 | JAMAPHARMA CONSULTING LLC | 3,666,667 | 0.49% | |
| 16 | NETWEALTH INVESTMENTS LIMITED |
3,454,893 | 0.47% | |
| 17 | BLJ TECHNOLOGIES PTY LTD | 2,920,019 | 0.39% | |
| 18 | Mi Ok Chong | 2,916,666 | 0.39% | |
| 19 | MS DEBORAH ANNE COLEMAN | 2,380,952 | 0.32% | |
| 20 | BNP PARIBAS NOMS PTY LTD |
2,241,137 | 0.30% | |
| TOTALS | 464,530,894 | 62.61% | ||
| Total Issued Capital | 741,935,748 | 100.00% |
==> picture [18 x 18] intentionally omitted <==
Holding is aggregated over a shareholder group
==> picture [10 x 10] intentionally omitted <==
Report generated on 03-Oct-2023 at 11:20 AM